Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 16/20 | 1.00 |
| ▸ | HSP90AB1 | P08238 | 16/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.71 |
| ▸ | HSP90B1 | P14625 | 3/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.59 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.59 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1966178 | 0.86 | HSP90AA1 (0.75) | HSP90AA1HSP90AB1ERBB2HSP90B1HDAC3 | |
| SCHEMBL1964645 | 0.83 | ERBB2 (1.00) | HSP90AA1HSP90AB1ERBB2HSP90B1 | |
| SCHEMBL1966701 | 0.82 | HSP90AB1 (0.75) | HSP90AA1HSP90AB1ERBB2HSP90B1 | |
| SCHEMBL1963694 | 0.82 | ERBB2 (0.81) | HSP90AA1HSP90AB1ERBB2HSP90B1 | |
| SCHEMBL27286422 | 0.82 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1ERBB2HSP90B1 | |
| SCHEMBL4900283 | 0.81 | HSP90AA1 (0.77) | HSP90AA1HSP90AB1ERBB2HSP90B1 | |
| SCHEMBL24145061 | 0.81 | HSP90AA1 (0.78) | HSP90AA1HSP90AB1ERBB2HSP90B1 | |
| SCHEMBL1962900 | 0.80 | ERBB2 (0.94) | HSP90AA1HSP90AB1ERBB2HSP90B1 | |
| SCHEMBL3130242 | 0.80 | HSP90AB1 (0.67) | HSP90AA1HSP90AB1ERBB2HSP90B1HDAC3 | |
| SCHEMBL27753548 | 0.79 | HSP90AB1 (0.65) | HSP90AA1HSP90AB1ERBB2HSP90B1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2336133-A1 | Purine analogs having HSP90-inhibiting activity | Conforma Therapeutics Corporation (US) | 2011-06-22 | — | — | EP | disclosed |
| EP-1962863-A2 | ORALLY ACTIVE PURINE-BASED INHIBITORS OF HEAT SHOCK PROTEIN 90 | Conforma Therapeutics Corporation (US) | 2008-09-03 | — | — | EP | disclosed |
| US-20080125446-A1 | Purine analogs having HSP90-inhibiting activity | CONFORMA THERAPEUTICS CORPORATION | 2008-05-29 | — | — | US | disclosed |
| US-7241890-B2 | Purine analogs having HSP90-inhibiting activity | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-07-10 | — | — | US | disclosed |
| WO-2007075572-A2 | ORALLY ACTIVE PURINE-BASED INHIBITORS OF HEAT SHOCK PROTEIN 90 | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070129334-A1 | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-06-07 | — | — | US | disclosed |
| US-20050049263-A1 | Purine analogs having hsp90-inhibiting activity | CONFORMA THERAPEUTICS CORPORATION | 2005-03-03 | — | — | US | disclosed |
| EP-1440072-A4 | PURINE ANALOGS HAVING HSP90-INHIBITING ACTIVITY | CONFORMA THERAPEUTIC CORP (US) | 2005-02-02 | — | — | EP | disclosed |
| EP-1440072-A2 | PURINE ANALOGS HAVING HSP90-INHIBITING ACTIVITY | Conforma Therapeutic Corporation (US) | 2004-07-28 | — | — | EP | disclosed |
| WO-2003037860-A2 | PURINE ANALOGS HAVING HSP90-INHIBITING ACTIVITY | CONFORMA THERAPEUTICS CORPORATION (US) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125446-A1 | Purine analogs having HSP90-inhibiting activity | HSP90B1, HSP90AB1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 2/4885ERBB2 3334/4885 |
| US-20070129334-A1 | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AA1 2/4885HSP90AB1 1/4885ERBB2 1609/4885 |
| US-20050049263-A1 | Purine analogs having hsp90-inhibiting activity | HSP90B1, HSP90AB1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 2/4885ERBB2 3334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.